Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 2
1989 2
1990 1
1991 5
1992 4
1993 6
1995 7
1996 6
1997 14
1998 19
1999 26
2000 30
2001 40
2002 29
2003 39
2004 34
2005 44
2006 34
2007 32
2008 52
2009 53
2010 65
2011 77
2012 68
2013 78
2014 71
2015 58
2016 75
2017 71
2018 69
2019 81
2020 92
2021 109
2022 84
2023 81
2024 30

Text availability

Article attribute

Article type

Publication date

Search Results

1,421 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: korhispana
Page 1
Showing results for mometasone korhispana
Your search for mometasona-korhispana retrieved no results
Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids.
Spada F, Barnes TM, Greive KA. Spada F, et al. Australas J Dermatol. 2018 Aug;59(3):e168-e174. doi: 10.1111/ajd.12762. Epub 2018 Feb 7. Australas J Dermatol. 2018. PMID: 29411351 Free PMC article. Review.
An extensive literature search of MEDLINE, Embase and other databases was conducted to review the safety and efficacy of various formulations of topical mometasone furoate. Mometasone furoate exhibits high potency with greater anti-inflammatory activit …
An extensive literature search of MEDLINE, Embase and other databases was conducted to review the safety and efficacy of various formulation …
Effectiveness of Intranasal Mometasone Furoate vs Saline for Sleep-Disordered Breathing in Children: A Randomized Clinical Trial.
Baker A, Grobler A, Davies K, Griffiths A, Hiscock H, Kubba H, Peters RL, Ranganathan S, Rimmer J, Rose E, Rowe K, Simpson CM, Davidson A, Nixon G, Perrett KP. Baker A, et al. JAMA Pediatr. 2023 Mar 1;177(3):240-247. doi: 10.1001/jamapediatrics.2022.5258. JAMA Pediatr. 2023. PMID: 36648937 Free PMC article. Clinical Trial.
Evidence from small clinical trials suggests that intranasal corticosteroids improve SDB as measured by polysomnography; however, the effect on symptoms and quality of life is unclear. OBJECTIVE: To determine whether intranasal mometasone furoate is more effective t …
Evidence from small clinical trials suggests that intranasal corticosteroids improve SDB as measured by polysomnography; however, the effect …
Allergic Rhinitis: A Review.
Bernstein JA, Bernstein JS, Makol R, Ward S. Bernstein JA, et al. JAMA. 2024 Mar 12;331(10):866-877. doi: 10.1001/jama.2024.0530. JAMA. 2024. PMID: 38470381 Review.
In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamine (eg, cetirizine, fexofenadine, desloratadine, loratadine) or an intranasal antihistamine (eg, azelastine, olopatadine), whereas patients w …
In addition, first-line treatment for mild intermittent or mild persistent allergic rhinitis may include a second-generation H1 antihistamin …
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Gevaert P, et al. J Allergy Clin Immunol. 2020 Sep;146(3):595-605. doi: 10.1016/j.jaci.2020.05.032. Epub 2020 Jun 7. J Allergy Clin Immunol. 2020. PMID: 32524991 Free article. Clinical Trial.
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Cong …
METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intran …
Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
Blair HA. Blair HA. Drugs. 2021 Apr;81(6):709-719. doi: 10.1007/s40265-021-01518-w. Epub 2021 Apr 19. Drugs. 2021. PMID: 33871819 Review.
Indacaterol/glycopyrronium/mometasone (Enerzair() Breezhaler()) is a fixed-dose combination of the long-acting beta(2) agonist (LABA) indacaterol, the long-acting muscarinic antagonist (LAMA) glycopyrronium and the inhaled corticosteroid (ICS) mometasone furoate …
Indacaterol/glycopyrronium/mometasone (Enerzair() Breezhaler()) is a fixed-dose combination of the long-acting beta(2) agonist (LABA) …
[Mometasone furoate].
Veien NK. Veien NK. Ugeskr Laeger. 1991 Sep 30;153(40):2848-50. Ugeskr Laeger. 1991. PMID: 1926632 Review. Danish. No abstract available.
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level.
Lazarus SC, Krishnan JA, King TS, Lang JE, Blake KV, Covar R, Lugogo N, Wenzel S, Chinchilli VM, Mauger DT, Dyer AM, Boushey HA, Fahy JV, Woodruff PG, Bacharier LB, Cabana MD, Cardet JC, Castro M, Chmiel J, Denlinger L, DiMango E, Fitzpatrick AM, Gentile D, Hastie A, Holguin F, Israel E, Jackson D, Kraft M, LaForce C, Lemanske RF Jr, Martinez FD, Moore W, Morgan WJ, Moy JN, Myers R, Peters SP, Phipatanakul W, Pongracic JA, Que L, Ross K, Smith L, Szefler SJ, Wechsler ME, Sorkness CA; National Heart, Lung, and Blood Institute AsthmaNet. Lazarus SC, et al. N Engl J Med. 2019 May 23;380(21):2009-2019. doi: 10.1056/NEJMoa1814917. Epub 2019 May 19. N Engl J Med. 2019. PMID: 31112384 Free PMC article. Clinical Trial.
However, there was no significant difference in the response to mometasone or tiotropium, as compared with placebo. Among the patients with a low eosinophil level who had a differential treatment response, 57% (95% confidence interval [CI], 48 to 66) had a better response …
However, there was no significant difference in the response to mometasone or tiotropium, as compared with placebo. Among the patient …
Mometasone furoate.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2001 Nov 15;58(22):2140-1. doi: 10.1093/ajhp/58.22.2140. Am J Health Syst Pharm. 2001. PMID: 11760915 No abstract available.
Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate.
Ridolo E, Barone A, Nicoletta F, Paoletti G, Heffler E, Malvezzi L, Canonica GW. Ridolo E, et al. Expert Rev Clin Immunol. 2023 Jun;19(6):575-584. doi: 10.1080/1744666X.2023.2200165. Epub 2023 Apr 19. Expert Rev Clin Immunol. 2023. PMID: 37038974 Review.
A single medication with a rapid onset of action, acting on breakthrough symptoms too, would be advantageous, also in terms of patient compliance. AREAS COVERED: GSP301 (olopatadine 600 g - mometasone furoate 25 g) is a novel intranasal formulation, combining the se …
A single medication with a rapid onset of action, acting on breakthrough symptoms too, would be advantageous, also in terms of patient compl …
1,421 results